- Home
- IMNM vs FFC Comparison
IMNM vs FFC Comparison
Compare IMNM & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- FFC
- Stock Information
- Founded
- IMNM 2006
- FFC 1983
- Country
- IMNM United States
- FFC United States
- Employees
- IMNM N/A
- FFC N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- FFC Trusts Except Educational Religious and Charitable
- Sector
- IMNM Health Care
- FFC Finance
- Exchange
- IMNM Nasdaq
- FFC Nasdaq
- Market Cap
- IMNM 747.7M
- FFC 763.1M
- IPO Year
- IMNM 2020
- FFC N/A
- Fundamental
- Price
- IMNM $12.01
- FFC $15.82
- Analyst Decision
- IMNM Strong Buy
- FFC
- Analyst Count
- IMNM 5
- FFC 0
- Target Price
- IMNM $28.60
- FFC N/A
- AVG Volume (30 Days)
- IMNM 803.1K
- FFC 164.1K
- Earning Date
- IMNM 11-13-2024
- FFC 01-01-0001
- Dividend Yield
- IMNM N/A
- FFC 6.79%
- EPS Growth
- IMNM N/A
- FFC N/A
- EPS
- IMNM N/A
- FFC N/A
- Revenue
- IMNM $10,129,000.00
- FFC N/A
- Revenue This Year
- IMNM N/A
- FFC N/A
- Revenue Next Year
- IMNM N/A
- FFC N/A
- P/E Ratio
- IMNM N/A
- FFC N/A
- Revenue Growth
- IMNM N/A
- FFC N/A
- 52 Week Low
- IMNM $7.76
- FFC $11.90
- 52 Week High
- IMNM $30.96
- FFC $14.96
- Technical
- Relative Strength Index (RSI)
- IMNM 43.70
- FFC 46.93
- Support Level
- IMNM $12.99
- FFC $15.84
- Resistance Level
- IMNM $15.13
- FFC $16.03
- Average True Range (ATR)
- IMNM 0.93
- FFC 0.14
- MACD
- IMNM -0.16
- FFC 0.00
- Stochastic Oscillator
- IMNM 3.79
- FFC 24.32
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.